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ABSTRACT

Amethod is provided for reducing or preventing bacterioph
age attack on bacteria used in a cheese making process. The

method includes (a) treating a blocker peptide precursor
With a protease enZyme that hydrolyzes the precursor to

produce blocker peptides; (b) collecting the blocker peptides
so produced; (c) formulating a starter media With the blocker

References Cited

peptides; (d) groWing bulk cultures of cheese making bac

U.S. PATENT DOCUMENTS

groWn in the inoculated starter media to a fermentation

(56)

teria in the inoculated starter media; and (e) adding bacteria

3,998,700 * 12/1976

Keinbold et al. ............... .. 435/252.4

4,104,126

Young

*

8/1978

... ... ... .... ..

. . . . . . ..

435/5

4,282,255 *

8/1981 Sandine et al.

4,379,170
4,402,986

4/1983

Hettinga et a1. ..

426/7

9/1983

Sinkoff et al. ....................... .. 426/41

medium for producing cheese. The present invention also
includes a method of making cheese and cheese produced by
the method.

.. 426/40

17 Claims, 2 Drawing Sheets

U.S. Patent

0a. 2, 2001

Sheet 2 0f 2

US 6,297,042 B1

w0
_

_

,
w

_

_

_

_

_

u
_

_
_

_
_

_
_

_
_

_
_

_
_

_
_

_
_

_
_

_
_

_
_

_
_

u
_

Ari@93ER
O. 5
O. 75
0.25
PEPTIDE BLOCKER CO/VCEN 7R4 T/ON (?g/ml)

O
9

@iqé00mE$(:

8
7

6

5

%
L,

IE3

[IF
_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

~

_

_

2

_

_

_

_

0.25

_

_

_

_

_

_

_

_

_

0.5

_

_

_

m

_

_

_

_

_

_

_

_

_

_

_

_

_

_

_

0.75

PEPT/DE BLOCK/5R CONCENTRA T/ON (mg. m.)

' 5

m

_

US 6,297,042 B1
1

2

CHEESE MAKING WITH BACTERIOPHAGE
RESISTANT BACTERIA

proliferation and attacks on starter cultures are desired.

ToWard this end, hoWever, it should be appreciated that
attempts to isolate phage-resistant strains have generally not

TECHNICAL FIELD

met With success. A need is therefore identi?ed for an

improved method of controlling bacteriophage attacks on
lactic acid bacteria utiliZed in the cheese making process.

The present invention relates generally to the art of cheese
making and, more particularly, to a method of improving the

productivity of the cheese making process and the quality of
a cheese product by preventing bacteriophage attack on
bacteria used in the cheese making process.

SUMMARY OF THE INVENTION
1O

BACKGROUND OF THE INVENTION

Cheese is a milk product that is generally rich in ?avor
and contains many high-quality nutrients. There are a great
many varieties of cheese but all are produced in a similar
manner. First, raW or pasteuriZed milk is cultured, clotted by
acid, rennet or both. The resulting curd is then cut and

15

shaped into the desired form With or Without pressing. Fresh
cheeses such as cottage cheese or cream cheese do not

require any further processing. Other varieties of cheese are,
hoWever, subsequently cured or ripened to obtain a desired

bacteria and subsequently prevent attachment of bacterioph
ages so that the bacteria may continue to function normally,

consistency, ?avor and aroma. These characteristics are

fermenting milk sugar and producing the desired curd more
effectively and ef?ciently. As a direct consequence of the

produced by a partial breakdoWn of milk proteins and fat by
the action of microbial, milk and rennet enZymes.

The acid produced during the manufacture of cheese

Accordingly, it is a primary object of the present invention
to provide an improved method of reducing or preventing
bacteriophage attack on bacteria used in the cheese making
process, overcoming the above-described limitations and
disadvantages of the prior art.
An additional object of the present invention is to provide
a simple and effective method of controlling bacteriophage
attacks on lactic acid bacteria used in the cheese making
process Wherein the bacteria are protected against attack.
Speci?cally, blocker peptides are produced and collected.
These blocker peptides attach to sites on the cheese making

25

results from the fermentation of the milk sugar, lactose.

resulting faster processing time, if any bacteriophage infec
tion does take place it is limited and localiZed and, therefore,
does not have a substantial adverse effect on the resulting

Generally, this fermentation is initiated by the addition to the

cheese product. Superior quality and greater productivity is

milk of a culture of specially selected acid bacteria. KnoWn
as a starter culture, many different types of lactic acid
bacteria may be utiliZed for this purpose. The acid produc

therefore insured.

tion in the cheese curd resulting from the activity of the
starter culture advantageously functions to retard the groWth
of other bacteria that Would otherwise cause undesirable
fermentations in the cheese. Further, the acid production also
favors the expulsion of the Whey and the fusion of the curd

Still another object of the present invention is to provide
a related method of making cheese With bacteriophage
resistant cheese making bacteria as Well as a relatively high
quality cheese With more uniform consistency, ?avor and
aroma.

35

particles.
The lactic acid starter cultures utiliZed in cheese making
may comprise single or mixed strains of bacteria. All,
hoWever, must convert milk sugar in the curd into lactic acid
Within a reasonable time if a high quality cheese is to result.

Several factors may, hoWever, prevent this conversion. Of
these factors, the most important is bacteriophage attack.
Speci?cally, cheese production loss due to phage attacks on
lactic culture is the number one problem faced by the dairy

products industry today.

pointed out in the appended claims.
To achieve the foregoing and other objects, and in accor
dance With the purposes of the present invention as
45

Bacteriophages or phages, are viruses that attack a lactic

described herein, a method is provided for controlling (e.g.
reducing or preventing) bacteriophage attack on bacteria
such as lactic acid bacteria starter culture used in a cheese

acid bacteria cell, commandeer the biosynthetic or repro

making process. The method includes the steps of treating a
blocker peptide precursor selected from a group consisting
of a source of immunoglobulins, bacteriophages, bacte
riophage parts or mixtures thereof With a protease enZyme
that hydrolyZes the blocker peptide precursor. The method

ductive machinery of the cell, produce neW phages and in
the process lyse the bacteria cell. Phages are prevalent in
cheese making facilities. They may contaminate the milk in
a number of Ways including through use of infected starter
cultures or through contact With phage-carrying dust par
ticles.

Phages effectively sloW doWn or totally inhibit the activity

Additional objects, advantages and other novel features of
the invention Will be set forth in part in the description that
folloWs and in part Will become apparent to those skilled in
the art upon examination of the folloWing or may be learned
With the practice of the invention. The objects and advan
tages of the invention may be realiZed and obtained by
means of the instrumentalities and combinations particularly

also includes the collecting of the blocker peptides produced
by the hydrolysis of the blocker peptide precursor and the
55

formulating and heat treating of a starter media With the

medium is often insuf?ciently soured and insuf?cient acid is
produced to retard the groWth of undesirable bacteria that
cause undesired fermentation products. Hence, the cheese

blocker peptides. Finally, the method includes the additional
steps of groWing bulk cultures of bacteria used in the cheese
making process in a peptide containing starter media and
adding the bacteria groWn in the peptide containing starter

spoils resulting in an undesired consistency, ?avor, and/or

media to a fermentation medium for producing cheese.

aroma.

More speci?cally describing the invention, the source for
immunoglobulins may include raW Whey, dried Whey, Whey
protein isolates, non-fat dried milk, blood serum protein

of the starter culture. As a result, the milk fermentation

It is knoWn that phage multiplication is in?uenced by
temperature, pH and calcium content of the medium among
other factors. While phage outbreaks can be at least partially

controlled by rigorous hygienic handling of starters, by
culture rotation and/or by culturing starters in calcium

reduced media, further improvements in controlling phage

65

isolates, puri?ed immune protein preparations and mixtures
thereof. Preferably, the bacteriophage parts includes spikes,
tail ?bers, ?laments and mixtures thereof. Also, the enZyme
used in the present method is preferably selected from a

US 6,297,042 B1
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The bacteriophage parts are preferably spikes, tail ?bers,

group consisting of papain, bromelain, ?cin and mixtures
thereof. Of these, papain appears to be the most preferred

?laments and mixtures thereof. Still more speci?cally, the

enzyme.
In accordance With a further aspect of the present

bacteriophages and parts thereof utiliZed as blocker peptide

invention, a method of making cheese With bacteriophage
resistant cheese making bacteria is provided. In addition to
the above steps, this method includes the cutting of the curd.

bacteria are sensitive. Generally, such cheese making bac
teria include lactic acid bacteria such as available, for
example, from CHR. Hansen’s of Mississauga, Ontario
including but not limited to mesophilic homofermentative,
thermophilic and mesophilic aromatic cultures as marketed
under the trademarks PHAGE CONTROL, DVS, PHAGE

precursors are of a type or strain to Which cheese making

Speci?cally, the curd is cut at a selected time in an effort to

increase cheese yield and maximiZe the result and quality of
the cheese. For example, the curd may be cut in accordance
With the method set forth in my co-pending US. Pat. No.

10

HARDENED, REDI-SET, SCO, ST/LH/LB, HR/HC,
ITALIANO, CH-N, PS, DSG, CAF and FLORA DANICA.

5,172,193 entitled “Method of Predicting Cut-Time of Milk
Coagulum in Cheese-Making Process”. Further, the method
may include the additional step of curing the curd to provide
a cheese of desired consistency, ?avor and aroma. Any
knoWn method of curing may be utiliZed to produce a cheese

Of course, lactic acid starter cultures are available from

other sources including, for example, Rhone-Poulenc (e.g.
15

cremoris, and Streptococcus thermophilous cultures identi
?ed by culture numbers: D11-LF, D15, D30-LF, D37, D40

of desired qualities. Cheeses produced in accordance With
the present method are also the subject of the present

LF, D50, D52-LF, D62, D71, D75, D84, D107, D115, D120,
D175, D180-LF, D205, D210, D220, D230, D250, D265,
D270, D275, D509-LF, L12, M30, M32, M46, M49, M56,

invention.

Still other objects of the present invention Will become
apparent to those skilled in this art from the folloWing
description Wherein there is shoWn and described a preferred

M58, M59, EZ 10, EZ 15, EZ 20, EZ 25, LF2, LF3, DPL
569, DPL 571, DPL 572, DPL 573, DPL 574, DPL 575, DPL
576, DPL 577, DPL 578, DPL 579, MA011, MA014,
MA016, MA019, EZ100, EZ200, EZ300; various thermo

embodiment of this invention, simply by Way of illustration
of one of the modes best suited to carry out the invention. As

it Will be realiZed, the invention is capable of other different

25

cus and Lactobacillus delbruekeii ssp. lactis cultures With

cation in various, obvious aspects all Without departing from

the folloWing culture numbers: C90, C100, C110, C120,

the invention. Accordingly, the draWings and descriptions

C130, C150, C160, C180, C260, C280, C300, C310, C320,
C330, C340, R110, R130, R150, R160, RX160, R170,
R180, R190, TC120, TC234, TC246, TC257, TR160, TEX
1, TEX 2, TEX 3, CR5, CR12, CR14, LBST, KCR5, TA052,

Will be regarded as illustrative in nature and not as restric

tive.
BRIEF DESCRIPTION OF THE DRAWING

TA054, TA060, TA061, TA062, LH100, LB120; as Well as
additional mixed and pure cultures including the above

The accompanying draWing incorporated in and forming
35

cremoris, Bi?dobacterium, Lactobacillus acidophilus, Lac
tococcus lactis ssp. lactis, Lactobacillus casei,

bacteria starter culture as a control With starter culture

Propionibacterium, Freudenrecheii ssp. shermanii, Bi?a'o
bacterium infantis, Bi?dobacterium longum including cul
ture numbers: 801—805, 811—815, 831—835, 851—855,

inoculated in accordance With the teachings of the present
invention in various concentrations folloWed by phage intro
duction at various concentrations;
FIG. 2 is a graphical representation of the effect of peptide
blocker concentration on the lag time before cell lyses
45

FIG. 3 is a graphical representation of the effect of peptide
blocker concentration on the rate of lysing of lactic acid
bacteria cells.
Reference Will noW be made in detail to the present

901—905, 911—915, 921—925, 951—953, 201—205, VT3, OS,
LD, FCS24, FLD, FMQ3, FOS, FRI, FVT3, Y604, Y605,
Y610, Y611, Y612, Y613, Y617, Y650, Y651, Y653, ABY
2C, THY35, THY42, THY95, CAF, JVI, BC1, BC2, MD
series, MM series, LC-20, FB302, FB304, PS31, TC120,
TC234, LC, NCFM, NCFM, BBI, 403 AC, 410 BBI, 411
BBL. The enZyme utiliZed to hydrolyZe the blocker peptide
precursor may be selected from a group of protease enZymes

including, for example, papain, bromelain, ?cin and mix
tures thereof. Preferably, papain is utiliZed. Papain cleaves
the immunoglobulin IgG and IgM blocker peptide precur

preferred embodiment of the invention, an example of Which
is illustrated in the accompanying draWing.
DETAILED DESCRIPTION OF THE
INVENTION

A method of controlling bacteriophage attack on bacteria

species alone or in combination With Lactococcus lactis ssp.

lactis biovar diacetylactis, Leuconostoc mesenteroides ssp.

explain the principles of the invention. In the draWing:
FIG. 1 is a graphical representation comparing lactic acid

begins folloWing introduction of bacteriophage;

philic cultures including Streptococcus thermophilous, Lac
tobacillus delbruekeii ssp. bulaaricus, Lactobacillus helveti

embodiments and its several details are capable of modi?

a part of the speci?cation, illustrates several aspects of the
present invention and together With the description serves to

various Lactococcus, lactis ssp., Lactococcus lactic ssp.

sors at a most advantageous location to provide phage

blocking activity. For best results, the concentration of
55

used in a cheese making process Will noW be described in

blocker peptide precursor to enZyme should be maintained
betWeen 0.2—50.0 grams per 100 lbs of precursor (at a

concentration of approximately 5% solids) and more pref

detail. The method includes the initial step of treating a
blocker peptide precursor selected from a group consisting
of a source of immunoglobulins, bacteriophages, bacte
riophage parts and mixtures thereof With a protease enZyme

erably should be maintained at about 1 gram per 100 lbs of

that hydrolyses the blocker peptide precursor. Preferably, the

precursor (at a concentration of approximately 5% solids).
More particularly, the production of the blocker peptides
may be completed in accordance With ultra?ltering and

source of immunoglobulins includes raW Whey, dried Whey,

dia?ltering techniques. Preferably, the blocker peptide pre

Whey protein isolates, non-fat dried milk, blood serum

cursor being treated With the enZyme is ultra?ltered through

protein isolates, puri?ed immune protein preparations and
mixtures thereof. It should be appreciated, hoWever, that this
list is presented only for purposes of illustration and the
invention should not be considered as limited thereto.

a polysulfone membrane cellulose or other membrane hav
65

ing a molecular Weight cut-off of less than 20,000 Daltons.

The permeate, that is, the material passing through the
membrane, comprises peptides having a molecular Weight of

US 6,297,042 B1
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less than 10,000—20,000 Daltons, depending on the siZe of
the membrane utilized in ?ltering.
As the blocker peptide permeate is collected, an appro

Accordingly, it should be appreciated that the present inven

priate dilutant (eg Water, Whey or pasteurized skim milk)

In accordance With still another aspect of the present
invention, a method of making cheese With bacteriophage
resistant cheese making bacteria further includes a step of
cutting the resulting curd that is formed in the fermentation
media by the activity of the cheese making bacteria. The
cutting of the curd may be accomplished in accordance With

tion both increases productivity While also ensuring a more

uniform and higher quality end product.

may be added to the source of immunoglobulins treated With
the enZyme. This is done volume-for-volume so that the

original volume of the blocker peptide precursor and
enZyme (i.e., the retentate) is substantially maintained at a
given level. This serves to maintain substrate concentrations

and reduce product inhibition. The enZymatic treatment of
the blocker peptide precursor is completed at any appropri

10

ate temperature Where enZymatic inactivation does not

occur. HoWever, temperatures just beloW the enZyme’s point
of denaturation are most efficient. Accordingly, for papain,
the enZymatic treatment is completed betWeen 30—50° C.
and most preferably at approximately 40° C. Further, the
enZymatic treatment is completed for a relatively extended

15

period of time of at least tWo hours. This alloWs the enZyme

to hydrolyZe signi?cant portions of the blocker peptide
precursor. Of course, a greater concentration of enzyme may

20

be used to shorten the processing time.

any appropriate means knoWn in the art at a time that may,

for example, be identi?ed by utiliZing any of the methods set
forth in my co-pending US. Pat. No. 5,172,193.
Further, the cheese making method may also include the
step of curing the curd to provide a cheese of desired
consistency, ?avor and aroma. As is knoWn in the art, curing
consists of a series of biological and chemical changes that
are affected by the moisture content, acidity, texture, shape,
siZe, and microorganisms in the cheese. The chemical
changes may include the breakdoWn of fats to fatty acids,
proteins to amino acids, and lactose to various products
including lactic, acidic and propionic acids, diacetyl, as Well

After collecting the blocker peptides produced by the

as carbon dioxide. Some of the ?avorful products of the

hydrolysis of the blocker peptide precursor, the blocker
peptides may be concentrated if desired utiliZing, for

curing process include various volatile fatty acids, alcohols,
esters, ketones, peptides, and amino acids produced during

example, reverse osmosis or evaporation in accordance With

procedures Well knoWn in the art. These peptides may then
be dried by using freeZe drying, spray drying, or vacuum
drying techniques also Well knoWn to those in the art. These
dried blocker peptides may then be subsequently formulated
into useable preparations or lactic groWth media by, for
example, mixing With appropriate carriers such as
phosphate, citrate, buffers or Water and groWth stimulants

25

The advantageous effect of the method of the present
invention produced by the peptide blockers on phage pro
liferation in a lactic acid bacteria culture is best demon
strated With reference to FIGS. 1—3. The phage concentra
30

such as yeast extract.

Next is the step of inoculating a groWth or starter media
With the blocker peptides. Such starter media for cheese
making bacteria are Well knoWn in the art. Preferably, the
starter media is formulated With blocker peptides having a
concentration of about 5.0% dry Weight When using a starter
media in poWered form. The starter media and peptide
blocker premix is then mixed With distilled Water. For best
effect, the concentration of blocker in the groWth or starter
media after mixing With distilled Water should at least be 0.5

35

heat treated using traditional methods knoWn by those

that the antigenic binding sites on the surface of the lactic
40

tration of 0.5 mg/ml of blocker is added to the groWth media.

45

contaminated the starter media. The starter media is then
50

petitive inhibition is observed betWeen the phage and the
blockers for the antigenic sites. Advantageously, When uti
liZing the blocker peptides in the present method, cheese vat
phage proliferation is inhibited suf?ciently so that the curd

may be completely coagulated for cutting before phage
attack becomes a signi?cant problem adversely effecting
quality of the cheese product.
The folloWing examples are presented to further illustrate
the invention, but are not to be considered as limited thereto.

inoculated starter media to a fermentation media (eg raW or 55

pasteuriZed milk) for producing cheese.

EXAMPLE 1
Blocker peptides Were prepared from a rennet Whey
blocker peptide precursor. Speci?cally, 5000 ml of rennet

Whey Were treated With 500 mg of crude papain (Sigma

Chemical Co., St. Louis, Mo.) While being ultra?ltered and
dia?ltered using a holloW ?ber membrane (Supelco,
Bellefonte, Pa.) With a molecular Weight cut-off of 10,000
60

Daltons. The process ran for tWo hours at 40° C. The
permeate Was collected and freeZe dried air dried for sub

sequent use as blocker peptides in controlling bacteriophage
attack on bacteria in accordance With the present method.

accordingly, (While unlikely) if any bacteriophage infection
does take place it is limited and localiZed. Thus, such a
bacteriophage infection does not have any substantial
adverse effect on the quality of the resulting cheese product.

bacteria cells are not competitively bound until a concen

At blocker concentrations greater than 0.5 mg/ml, a com

minutes, to destroy any microorganisms that may have

Advantageously, the blocker peptides bind and block
binding sites/determinates on the bacteria thereby providing
a competitive inhibition to subsequent phage attack.
Accordingly, the cheese making bacteria continue to func
tion normally fermenting the milk sugar and producing the
desired curd more effectively and ef?ciently. In fact, fer
mentation processing time may be signi?cantly reduced and,

resulting increase in lag times (that is, the time from phage
addition to point Where rate of lysis exceeds cultured

skilled in the art at temperatures such as 85° C. for 45

cooled for temperatures that supports the lactic culture of
choice.
Next is the groWing of.bulk cultures of bacteria used in
the cheese making process in this inoculated starter media.
This is folloWed by adding the bacteria groWn in the

tion at the point of inoculation Was 8.4><105/ml. Peptide
blocker concentration includes approximately 72% lactose.
As clearly demonstrated in FIG. 1, peptide blockers can
inhibit phage attachment to lactic cells (Lactococcus lactis
ssp. lactis WWA4). FIG. 2 graphically demonstrates the

groWth). FIG. 3 graphically demonstrates the resulting
decrease in the lysis rate. Together, this data clearly suggests

mg/ml.
Lactic starter media containing blocker peptides are then

this process.

65

EXAMPLE 2
Blocker peptides are prepared from a rennet Whey blocker

peptide precursor. Speci?cally, 5000 ml of rennet Whey is

US 6,297,042 B1
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treated With 500 mg of bromelain (ICN Biomedicals, Inc.,

Iruine, Calif.) While being ultra?ltered and dia?ltered using

?ber Romicon ultra?ltration membrane, Were used to pre
pare a phage inhibitory medium. Bulk starter Was prepared

a hollow ?ber membrane (Supelco, Bellefonte, Pa.) With a
molecular Weight cut-off of 10,000 Daltons. The process

from M17 broth inoculated (4%) With WWA-SCO166-4
single strain lactic culture. M17 broth (heat treated at 85 C

runs for tWo hours at 40° C. The permeate is collected and
freeZe dried or air dried for subsequent use as blocker

for 45 min and cooled to 24 C) containing Whey peptide
blockers (0, 0.025, 0.05, 0.075, and 0.1 g/mL) Was inocu

peptides in controlling bacteriophage attack on bacteria in
accordance With the present method.

lated With WWA-SCO 166-4 bulk starter and incubated for
6.0 hours. WWA4-phage Were added to the groWing culture

EXAMPLE 3

10

Blocker peptides are prepared from a rennet Whey blocker

peptide precursor. Speci?cally, 5000 ml of rennet Whey is
treated With 100 mg of ?cin (ICN Biomedicals, Inc., Irvine,
Calif.) While being ultra?ltered and dia?ltered using a hol
loW ?ber membrane (Supelco, Bellefonte, Pa.) With a
molecular Weight cut-off of 10,000 Daltons. The process

15

20

EXAMPLE 4

1><109 cfu/ml) is added to groWth or starter media M17.

25

linearly With phage concentration suggesting that blocker
concentration Was most effective When lactic cell numbers

What is claimed is:
1. Amethod of controlling bacteriophage attack on cheese
30

tail ?bers and ?laments is then hydrolyzed With one or more

making bacteria used in a cheese making process, compris
mg:
treating a blocker peptide precursor selected from a group

consisting of a source of immunoglobulins, bacterioph
ages to Which cheese making bacteria are sensitive,

protease enZymes such as papain, bromelain or ?cin. EnZy

matic hydrolysis takes place While the suspension is being

other experiments Where phage concentration varied from
101 to 103 pfu/mL, time to maximum absorbance decreased

Were loWest.

The disrupted suspension of phage parts including spikes,

ultra?ltered and dia?ltered using a holloW ?ber membrane

tions of 0.05 to 0.1 g/mL, suggesting that antigenic sites on
the surface of lactic cells must be saturated before the
attachment of phage could be competitively inhibited. In
as phage concentration increased. HoWever, the time differ
ential betWeen media With and Without blockers increased

phage speci?c to the lactic bacteria groWn in the starter
media) is added to the culture. After approximately 120—150

minutes, the phage lyse all bacteria cells. The medium
containing the phage is then disrupted using a tissue
homogeniZer, blender, sonicator or other disruptive device.

(0.1 g/mL blocker). Slope of bacterial lysis did not change
until blocker concentration exceeded 0.05 g/ml. A linear
decrease in lysis rate Was observed for blocker concentra

Lactic bacteria (Lactococcus lactis ssp. lactis WWA4,

After 90 minutes, bacteriophage c2 (2><107 pfu/ml) (i.e. a

peptide blocker concentration increased the time to bacterial
cell lysis increased and the rate of bacterial lysis decreased.
Time from phage introduction to maximum absorbance

increased linearly from 85 min (0 g/ml blocker) to 147.5 min

runs for tWo hours at 40° C. The permeate is collected and
freeZe dried or air dried for subsequent use as blocker

peptides in controlling bacteriophage attack on bacteria in
accordance With the present method.

(103 pfu/mL) after 90 min of incubation. Cell groWth Was
monitored spectrometrically (A?oomn) at 10 min intervals. As

35

bacteriophage parts to Which cheese making bacteria
are sensitive and mixtures thereof With a protease

With a molecular Weight cut-off of, for example, 10,000

enZyme that hydrolyZes the blocker peptide precursor;

Daltons. The process runs for 2 hours at approximately 40°
C. The permeate is collected and may be freeZe dried air

collecting blocker peptides produced by hydrolysis of the

dried by any appropriate method knoWn in the art. The
permeate may then be subsequently utiliZed in the method of
the present invention to control bacteriophage attack on
bacteria used in the cheese making process.

blocker peptide precursor;
40

groWing bulk cultures of cheese making bacteria used in
the cheese making process in the formulated starter

EXAMPLE 5
45

Lactococcus lactis ssp. lactis C2 bulk starter (incubated at
26° C. for 16 hours in M17 broth) Was used to inoculate

(2%) media consisting of M17 broth With CaCl2 (3 samples)
and M17 broth With CaCl2 plus fractionated Whey peptide
blocker (4%) (2 samples). Phage c2 (2><107 pfu/ml) Was
added (1%) to four incubating cultures (26 C) (tWo With

50

isolates, puri?ed immune protein preparations and mixtures
riophage parts include spikes, tail ?bers, ?laments and
55

proliferation and decreased rate of cell lysis. Media With
blocker extended cell groWth time by 29.8 and 21.5 min for
cultures inoculated With bacteriophage at 30 and 60 min,

riophage parts include spikes, tail ?bers, ?laments and
60

lysis Were observed When cells Were groWn in blocker

containing media inoculated With bacteriophage at 30 and 60

min, respectively.
EXAMPLE 6

lected through a 10,000 molecular Weight cut off holloW

mixtures thereof.
4. The method set forth in claim 1, Wherein said bacte
mixtures thereof.
5. The method set forth in claim 1, Wherein said enZyme

respectively. Rate of lysis generally increased With cell

Peptides, fractionated from hydrolyZed Whey, and col

immunoglobulins includes raW Whey, dried Whey, Whey
protein isolates, non-fat dried milk, blood serum protein
thereof.
3. The method set forth in claim 1, Wherein said bacte

inoculation. Cell groWth Was observed (A?oonm) immedi
ately after culture inoculation and at 20 min intervals for 5

numbers. HoWever, 55% and 52.5% reductions in rate of cell

media; and
adding cheese making bacteria groWn in the formulated
starter media to a fermentation medium for producing
cheese.
2. The method set forth in claim 1, Wherein said source of

blocker, tWo Without) at 30 min or 60 min after culture

hours. Blocker-containing media inhibited bacteriophage

formulating a starter mediate With the blocker peptides
and heat treating the formulated starter media;

65

is selected from a group consisting of papain, bromelain,
?cin and mixtures thereof.
6. The method set forth in claim 2, Wherein said enZyme
is selected from a group consisting of papain, bromelain,
?cin and mixtures thereof.
7. The method set forth in claim 3, Wherein said enZyme
is selected from a group consisting of papain, bromelain,
?cin and mixtures thereof.

US 6,297,042 B1
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10
collecting blocker peptides produced by hydrolysis of the

8. The method set forth in claim 4, wherein said enzyme
is selected from a group consisting of papain, bromelain,
?cin and mixtures thereof.

blocker peptide precursor, said collected blocker pep
tides being utiliZed to inoculate the starter media.
12. The method set forth in claim 11, Wherein said source

9. A method of making cheese With bacteriophage resis

of immunoglobulins include raW Whey, dried Whey, Whey
protein isolates, non-fat dried milk, blood serum protein
isolates, puri?ed immune protein preparations and mixtures

tant cheese making bacteria, comprising:
formulating a starter media With peptides that block
bacteriophage attachment sites on the cheese making

thereof.
13. The method set forth in claim 12, Wherein said

bacteria;
groWing bulk cultures of the cheese making bacteria in the
formulated starter media;
adding the cheese making bacteria groWn in the formu

10

10. The method set forth in claim 9, including a further
step of curing the curd to provide a cheese of desired
consistency, ?avor and aroma.
11. The method set forth in claim 10, further including:
treating a blocker peptide precursor selected from a group
consisting of a source of immunoglobulins,

bacteriophages, bacteriophage parts and mixtures

mixtures thereof.
14. The method set forth in claim 10, Wherein said

bacteriophage parts include spikes, tail ?bers, ?laments and

lated starter media to a fermentation media for produc

ing cheese Whereby a curd is formed; and
cutting the curd.

bacteriophage parts include spikes, tail ?bers, ?laments and

15

mixtures thereof.
15. The method
enZyme is selected
bromelain, ?cin and
16. The method
enZyme is selected
bromelain, ?cin and
17. The method
enZyme is selected
bromelain, ?cin and

set forth in claim 10, Wherein said
from a group consisting of papain,
mixtures thereof.
set forth in claim 12, Wherein said
from a group consisting of papain,
mixtures thereof.
set forth in claim 14, Wherein said
from a group consisting of papain,
mixtures thereof.

thereof With a protease enZyme that hydrolyzes the

blocker peptide precursor; and
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